Platelet activating factor levels and metabolism in tangier disease: a case study

被引:4
|
作者
Kolovou, Vana [1 ,2 ,3 ]
Papakonstantinou, Vasiliki D. [3 ]
Stamatakis, George [3 ]
Verouti, Sophia N. [3 ]
Xanthopoulou, Marianna N. [4 ]
Kolovou, Genovefa [1 ,2 ]
Demopoulos, Constantinos A. [3 ]
机构
[1] Onassis Cardiac Surg Ctr, Dept Cardiol, Athens, Greece
[2] Onassis Cardiac Surg Ctr, Mol Immunol Lab, Athens, Greece
[3] Univ Athens, Fac Chem, Biochem Lab, Athens 11528, Greece
[4] Harokopio Univ, Dept Sci Nutr Dietet, Athens, Greece
关键词
PAF; Tangier Disease; Atherosclerosis; Lp-PLA(2); PAF-AH; Lyso-PAF-AT; PAF-CPT; ACETYLHYDROLASE PAF-AH; CASSETTE TRANSPORTER 1; DENSITY-LIPOPROTEIN; PHOSPHOLIPASE A(2); PLASMA; BINDING; CHOLESTEROL; BLOOD; VIVO; LEUKOCYTES;
D O I
10.1186/1476-511X-11-89
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Tangier disease (TD) is a phenotypic expression of rare familial syndrome with mutations in the ABCA1 transporter. The risk of coronary artery disease in patients with TD is variable. On the other hand the pivotal role of Platelet-Activating Factor (PAF) mediator in atheromatosis was found. Plasma lipoproteins are transporters of the PAF acetylhydrolase (PAF-AH) in cells and known as lipoprotein-phospholipase A(2) (Lp-PLA(2)) in plasma and regulators of PAF levels in blood. In addition, PAF can be biosynthesized from the remodeling and the de novo pathways in which Lyso-platelet activating factor-acetyltransferase (Lyso-PAF-AT) and platelet activating factor-cholinephosphotransferase (PAF-CPT) are the regulatory enzymes. The aim of this study is to investigate in a TD patient with a unique mutation (C2033A), the concentration of PAF in blood, the Equivalent Concentration for 50% aggregation (EC50) values of platelet rich plasma (PRP) toward PAF, adenosine diphosphate (ADP) and thrombin, and the activities of PAF metabolic enzymes Lp-PLA(2), PAF-AH, Lyso-PAF-AT and PAF-CPT. Methods: The EC50 value of PRP was measured by an aggregometer. The determination of the specific activity of PAF-CPT and Lyso-PAF-AT was made after in vitro enzymatic assay, chromatographic separation and measurement of the produced PAF in a biological assay with washed rabbit platelets. The determination of PAF-AH and Lp-PLA(2) was made after an in vitro enzymatic assay from the decay of radioactive PAF. Results: The TD patient had lower bound-PAF values in blood, decreased specific activity of PAF-CPT and Lyso-PAF-AT, increased specific activity of PAF-AH in platelets and leukocytes and Lp-PLA(2) activity in plasma compared to healthy women. The EC50 of PAF and Thrombin were higher compared to healthy women. Conclusion: The increased Lp-PLA(2) activity, as well as, the decreased activities of PAF-CPT and Lyso-PAF-AT, explain the decreased bound-PAF level in TD patient and the EC50 of PAF. However, total PAF is in a normal range and this probably can explain one of the reasons this TD patient has no CAD.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] PLATELET ACTIVATING FACTOR
    BENVENISTE, J
    REVUE FRANCAISE D ALLERGOLOGIE ET D IMMUNOLOGIE CLINIQUE, 1977, 17 (02): : 79 - 81
  • [32] METABOLISM OF PLATELET-ACTIVATING-FACTOR IN THE GUINEA-PIG HEART
    TRIGGIANI, M
    CHILTON, FH
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1992, 24 (10) : 1101 - 1111
  • [33] METABOLISM OF PLATELET-ACTIVATING FACTOR BY BLOOD-PLATELETS AND PLASMA
    ALAM, I
    SMITH, JB
    SILVER, MJ
    LIPIDS, 1983, 18 (08) : 534 - 538
  • [34] METABOLISM OF PLATELET-ACTIVATING-FACTOR IN ISOLATED PERFUSED RAT LUNG
    HAROLDSEN, PE
    VOELKEL, NF
    HENSON, JE
    HENSON, PM
    MURPHY, RC
    JOURNAL OF CLINICAL INVESTIGATION, 1987, 79 (06): : 1860 - 1867
  • [35] METABOLISM OF PLATELET-ACTIVATING-FACTOR (PAF) BY RABBIT RENAL HOMOGENATES
    CAGEN, LM
    YEH, YM
    BAER, PG
    FEDERATION PROCEEDINGS, 1986, 45 (06) : 1530 - 1530
  • [36] PLATELET-ACTIVATING-FACTOR AND LIPID-METABOLISM IN ACUTE MALARIA
    DAVIS, TME
    STURM, M
    ZHANG, YR
    SPENCER, JL
    GRAHAM, RM
    LI, GQ
    TAYLOR, RR
    JOURNAL OF INFECTION, 1993, 26 (03) : 279 - 285
  • [37] INTERRELATIONSHIPS IN THE METABOLISM OF PLATELET ACTIVATING FACTOR AND ARACHIDONIC-ACID IN NEUTROPHILS
    WYKLE, RL
    JOURNAL OF THE AMERICAN OIL CHEMISTS SOCIETY, 1984, 61 (04) : 674 - 674
  • [38] BINDING AND METABOLISM OF PLATELET-ACTIVATING-FACTOR BY HUMAN-NEUTROPHILS
    OFLAHERTY, JT
    SURLES, JR
    REDMAN, J
    JACOBSON, D
    PIANTADOSI, C
    WYKLE, RL
    JOURNAL OF CLINICAL INVESTIGATION, 1986, 78 (02): : 381 - 388
  • [39] THE METABOLISM OF PLATELET-ACTIVATING FACTOR IN HUMAN T-LYMPHOCYTES
    TRAVERS, JB
    SPRECHER, H
    FERTEL, RH
    BIOCHIMICA ET BIOPHYSICA ACTA, 1990, 1042 (02) : 193 - 197
  • [40] TOPOGRAPHY OF PLATELET-ACTIVATING-FACTOR METABOLISM IN VARIOUS CELL MODELS
    RECORD, M
    RIBBES, G
    LUMB, R
    NINIO, E
    VALLARI, D
    SNYDER, F
    CHAP, H
    JOURNAL OF LIPID MEDIATORS AND CELL SIGNALLING, 1994, 10 (1-2): : 3 - 5